Genesys Capital
Genesys Capital is focused on building companies in the high-growth sectors of healthcare and biotechnology.
Business Model:
Revenue: $7.2M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Genesys Capital Information
Geographic Data
Address: 36 Toronto Street
City: Toronto
State: ontario
Zip: M5C 2C5
Country: CA
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
5,522,242Website Global Rank
1,690Website Monthly Traffic
Twitter Followers
Description
Genesys Capital is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising biotechnology investment opportunities.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2012 | Naurex | Series B | 0 |
| 1/2018 | Flosonics | Equity | 5M |
| 4/2012 | Tioga Pharmaceuticals | Series B | 10M |
| 8/2006 | Millenium Biologix | Venture Round | 0 |
| 5/2017 | Therapeutic Monitoring Systems Inc. | Venture Round | - |
| 3/2007 | Affinium Pharmaceuticals | Series A | 18M |
| 2/2010 | Tioga Pharmaceuticals | Venture Round | 18M |
| 12/2013 | Invitae | Series E | 0 |
| 2/2021 | Flosonics | Venture Round | 0 |
| 7/2004 | NeurAxon | Series A | 1.9M |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 8/2007 | NeurAxon | Series B | 32M |
| 12/2017 | Aptinyx | Series B | 70M |
| 10/2022 | Inversago Pharma | Series C | 0 |
| 12/2014 | Naurex | Series C | 0 |
| 9/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 7/2009 | Allostera Pharma | Series A | 14.6M |
| 4/2015 | Profound Medical Inc | Venture Round | 0 |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 10/2014 | Invitae | Series F | 0 |
| 1/2020 | IDbyDNA | Series B | 0 |
| 5/2021 | Giiant Pharma | Seed Round | 0 |
| 9/2020 | Inversago Pharma | Series B | 0 |
| 7/2011 | gIcare Pharma | Series A | 7.4M |
| 7/2018 | Inversago Pharma | Series A | 0 |
| 11/2019 | EBT Medical | Series A | 10M |
| 5/2011 | Naurex | Series A | 18M |
| 2/2006 | StemPath | Venture Round | 1M |
| 1/2018 | Adapsyn Bioscience | Venture Round | - |
| 10/2011 | Functional Neuromodulation | Series A | 10.4M |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 5/2021 | Giiant Pharma | Seed Round | 0 |
| 2/2021 | Flosonics | Venture Round | 0 |
| 9/2020 | Inversago Pharma | Series B | 0 |
| 1/2020 | IDbyDNA | Series B | 0 |
| 11/2019 | EBT Medical | Series A | 0 |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 7/2018 | Inversago Pharma | Series A | 0 |
| 1/2018 | Flosonics | Seed Round | 0 |
| 1/2018 | Adapsyn Bioscience | Venture Round | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
